KG
Kalarani Ganesan
About Kalarani Ganesan
Data last updated:
Kalarani Ganesan has 21 years in corporate governance. Holds Director role. Currently with 3 companies, including Luminol Biopharma Private Limited and Sri Sai Clinical Research Institute Private Limited. Formerly with 1 company, such as Regenix Health Care Limited. Engaged in General Business, Healthcare. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
 Luminol Biopharma Private Limited U24304TN2017PTC116722 | Director | 24 May 2017 | 2017 | Active |
 Sri Sai Clinical Research Institute Private Limited U73100TN2009PTC070600 | Director | 29 Jan 2009 | 2009 | Active |
 Micro Therapeutic Research Labs Private Limited U85195TN2005PTC055378 | Director | 15 Feb 2005 | 2005 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
| Regenix Health Care Limited U24100TN2005PLC057698 | Director | 20 Mar 2010 | 2005 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Kalarani Ganesan
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kalarani Ganesan
Kalarani Ganesan has 21 years in corporate governance. Holds Director role. Currently with 3 companies, including Luminol Biopharma Private Limited and Sri Sai Clinical Research Institute Private Limited. Formerly with 1 company, such as Regenix Health Care Limited. Engaged in General Business, Healthcare. Contributes to corporate operations.
Kalarani Ganesan is associated with 3 companies as Director.
Kalarani Ganesan has expertise in General Business, Healthcare.
Kalarani Ganesan has 21 years in corporate governance.